Sixty consecutive patients with chronic hepatitis C were included in a randomized controlled trial of recombinant human interferon-%, vs. no treatment. Treated patients received tapering doses of interferon thrice weekly for 1 yr. Twenty treated cases (66.7%) normalized serum aminotransferase levels
Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial
✍ Scribed by Balart, L.A; Schiff, E.R; Lindsay, K; Bodenheimer, H.C; Perrillo, R.P; Carey, W; Davis, G.L; Jacobson, I.M; Payne, J; Dienstag, J.L
- Book ID
- 122764989
- Publisher
- Elsevier Science
- Year
- 1990
- Tongue
- English
- Weight
- 305 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Chronic hepatitis C is often a progressive liver disease for which there is no satisfactory treatment. We studied the efficacy of recombinant a-interferon or y-interferon in the treatment of this disease in comparison with a control group. Thirty patients were randomly assigned to three groups. Ten
AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC